{"log_id": 7637750400580565263, "direction": 0, "words_result_num": 25, "words_result": [{"probability": {"variance": 0.00094, "average": 0.989002, "min": 0.816316}, "location": {"width": 845, "top": 218, "height": 53, "left": 176}, "words": "甲状腺功能亢进。在治疗前促甲状腺激素(TSH)<5μU/mL的患者中,接受阿昔替尼"}, {"probability": {"variance": 0.005197, "average": 0.974853, "min": 0.646114}, "location": {"width": 845, "top": 275, "height": 50, "left": 176}, "words": "治疗的79245例患者(32%)及接受索拉非尼治疗的25232例患者(11%)的TSH升"}, {"probability": {"variance": 0.000278, "average": 0.991089, "min": 0.929662}, "location": {"width": 513, "top": 340, "height": 43, "left": 176}, "words": "高至10μU/mL或10μU/mL以上(见【不良反应】)。"}, {"probability": {"variance": 0.000178, "average": 0.996655, "min": 0.918878}, "location": {"width": 803, "top": 386, "height": 51, "left": 221}, "words": "在开始阿昔替尼治疗前应监测甲状腺功能,在阿昔替尼治疗期间应定期监测甲状腺"}, {"probability": {"variance": 5.3e-05, "average": 0.997643, "min": 0.965033}, "location": {"width": 847, "top": 441, "height": 51, "left": 178}, "words": "功能。应根据常规对甲状腺功能减退和甲状腺功能亢进进行治疗,以维持甲状腺功能正"}, {"probability": {"variance": 0, "average": 0.999865, "min": 0.999743}, "location": {"width": 69, "top": 518, "height": 26, "left": 180}, "words": "常状态"}, {"probability": {"variance": 0.000893, "average": 0.98426, "min": 0.911999}, "location": {"width": 162, "top": 568, "height": 29, "left": 180}, "words": "伤口愈合并发症"}, {"probability": {"variance": 0.00125, "average": 0.991168, "min": 0.837148}, "location": {"width": 454, "top": 612, "height": 41, "left": 225}, "words": "尚未开展阿昔替尼对伤口愈合影响的正式研究"}, {"probability": {"variance": 8.5e-05, "average": 0.997064, "min": 0.958673}, "location": {"width": 804, "top": 658, "height": 50, "left": 226}, "words": "应在预定手术前至少24小时停止阿昔替尼治疗。应根据伤口是否完全愈合的临床"}, {"probability": {"variance": 2e-06, "average": 0.998977, "min": 0.994223}, "location": {"width": 452, "top": 721, "height": 42, "left": 184}, "words": "判断,决定术后重新开始阿昔替尼治疗的时间"}, {"probability": {"variance": 0.000112, "average": 0.994194, "min": 0.95964}, "location": {"width": 277, "top": 780, "height": 37, "left": 183}, "words": "可逆性后部脑白质病综合征"}, {"probability": {"variance": 0.0154, "average": 0.957721, "min": 0.399985}, "location": {"width": 833, "top": 811, "height": 68, "left": 228}, "words": "在接受阿昔替尼治疗的RCC患者对照临床研究中,接受阿昔替尼治疗的1359例"}, {"probability": {"variance": 0.000859, "average": 0.992836, "min": 0.808565}, "location": {"width": 850, "top": 876, "height": 51, "left": 182}, "words": "患者(<1%)报告可逆性后部脑白质病综合征(RPLS),接受索拉非尼治疗的患者未报"}, {"probability": {"variance": 0.001936, "average": 0.985036, "min": 0.773339}, "location": {"width": 730, "top": 933, "height": 48, "left": 185}, "words": "告RPLS(见【不良反应】)。在阿昔替尼其他临床试验中报告了两例RPLS"}, {"probability": {"variance": 0.0001, "average": 0.996501, "min": 0.938885}, "location": {"width": 781, "top": 986, "height": 49, "left": 230}, "words": "RPLS是一种神经系统疾病,可能表现为头痛、癫痫发作、昏睡、意识模糊、失明"}, {"probability": {"variance": 0.000122, "average": 0.995733, "min": 0.933701}, "location": {"width": 847, "top": 1041, "height": 49, "left": 187}, "words": "其他视觉和神经系统紊乱。还可能出现轻度至重度高血压。核磁共振成像是确认RPLS"}, {"probability": {"variance": 1.5e-05, "average": 0.997276, "min": 0.980924}, "location": {"width": 847, "top": 1093, "height": 52, "left": 188}, "words": "诊断所必需的。出现RPLS的患者应停用阿昔替尼。曾出现过RPLS的患者再次给予阿"}, {"probability": {"variance": 5e-06, "average": 0.99806, "min": 0.991047}, "location": {"width": 252, "top": 1163, "height": 38, "left": 190}, "words": "昔替尼治疗的安全性未知"}, {"probability": {"variance": 7e-06, "average": 0.996696, "min": 0.993202}, "location": {"width": 71, "top": 1226, "height": 27, "left": 191}, "words": "蛋白尿"}, {"probability": {"variance": 0.012552, "average": 0.96597, "min": 0.459219}, "location": {"width": 802, "top": 1258, "height": 53, "left": 237}, "words": "在接受阿昔替尼治疗的RCC患者对照临床研究中,接受阿昔替尼治疗的39/359例"}, {"probability": {"variance": 0.005137, "average": 0.981806, "min": 0.542176}, "location": {"width": 846, "top": 1314, "height": 54, "left": 193}, "words": "患者(11%)和接受索拉非尼治疗的26/355例患者(7%)报告蛋白尿。接受阿昔替尼"}, {"probability": {"variance": 0.003247, "average": 0.986362, "min": 0.630714}, "location": {"width": 846, "top": 1368, "height": 55, "left": 195}, "words": "治疗的11359例患者(3%)和接受索拉非尼治疗的635例患者(2%)报告3级蛋白"}, {"probability": {"variance": 0.00011, "average": 0.994746, "min": 0.966727}, "location": {"width": 209, "top": 1441, "height": 38, "left": 194}, "words": "尿(见【不良反应】)"}, {"probability": {"variance": 0.002266, "average": 0.974697, "min": 0.844861}, "location": {"width": 137, "top": 1583, "height": 26, "left": 557}, "words": "第11页,共27页"}, {"probability": {"variance": 0, "average": 0.998595, "min": 0.997926}, "location": {"width": 17, "top": 1619, "height": 18, "left": 288}, "words": "20"}], "language": 3}